Kim, Y W <br/><br/>
Pharmacokinetics and tissue distribution of 3-((5-(6-methylpyridin-2-yl)-4-(quinoxalin-6-yl)-1H-imidazol-2-yl)methyl)benzamide; a novel ALK5 inhibitor and a potential anti-fibrosis drug.  [electronic resource] 

 -  Xenobiotica; the fate of foreign compounds in biological systems  Mar 2008 
 - 325-39 p.  digital 
<br/><br/> Publication Type: Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>0049-8254 
<br/><br/><label>Standard No.: </label>10.1080/00498250701781924  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Administration, Oral<br/>Animals<br/>Benzamides--administration & dosage<br/>Biological Transport--drug effects<br/>Caco-2 Cells<br/>Chromatography, Liquid<br/>Dogs<br/>Enzyme Inhibitors--administration & dosage<br/>Half-Life<br/>Haplorhini<br/>Humans<br/>Imidazoles--administration & dosage<br/>Injections, Intravenous<br/>Magnetic Resonance Spectroscopy<br/>Male<br/>Mass Spectrometry<br/>Mice<br/>Models, Biological<br/>Protein Serine-Threonine Kinases--antagonists & inhibitors<br/>Quinoxalines--administration & dosage<br/>Rats<br/>Rats, Sprague-Dawley<br/>Receptor, Transforming Growth Factor-beta Type I<br/>Receptors, Transforming Growth Factor beta--antagonists & inhibitors<br/>Tissue Distribution--drug effects